Prostaglandin-associated periorbitopathy in latanoprost users

Clinical Ophthalmology

Volumn 9, Issue , 2014, Pages 51-56

  Nakakura, Shunsuke ^a   Yamamoto, Minamai ^a   Terao, Etsuko ^a   Nagatomi, Nozomi ^a   Matsuo, Naoko ^a   Fujisawa, Yausko ^a   Fujio, Yuki ^a   Tabuchi, Hitoshi ^a   Kiuchi, Yoshiaki ^b  

^a Saneikai Tsukazaki Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Deepening of the upper eyelid sulcus; Glaucoma; Prostaglandin F2

Indexed keywords

LATANOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; EYE DISEASE; EYE PHOTOGRAPHY; EYELID DISEASE; FEMALE; GLAUCOMA; HUMAN; MALE; PROSTAGLANDIN ASSOCIATED PERIORBITOPATHY; PTOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84920594282     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S75651     Document Type: Article

References (28)

1. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–577.
2. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53(2):176–179.
3. Nakakura S, Tabuchi H, Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom Vis Sci. 2011;88(9):1140–1144.
4. Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. J Glaucoma. 2014;23(3):160–163.
5. Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latano­prost and travoprost. Clin Experiment Ophthalmol. 2014;42(2):126–131.
6. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626–631.
7. Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58(2):212–217.
8. Tan J, Berke S. Latanoprost-induced prostaglandin-associated perior­bitopathy. Optom Vis Sci. 2013;90(9):e245–e247; discussion 1029.
9. Yoshino T, Fukuchi T, Togano T, Seki M, Ikegaki H, Abe H. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013;57(2):172–178.
10. Pasquale LR. Prostaglandin-associated periorbitopathy: a postmarketing surveillance observation. Glaucoma Today [serial on the Internet]. 2011 Summer [cited 2014 Jun 10];(9):51–52; 58. Available from: http://bmctoday.net/glaucomatoday/pdfs/gt0611_thera_pasquale.pdf. Accessed November 6, 2014.
11. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638.
12. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55(6):600–604.
13. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57(2):179–184.
14. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741–764.
15. Nakakura S, Terao E, Nagatomi N, et al. Cross-sectional study of the association between a deepening of the upper eyelid sulcus-like appearance and wide-open eyes. PLoS One. 2014;9(4):e96249.
16. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55(1):22–27.
17. Lee GA, Ritch R, Liang SY, et al. Tight orbit syndrome: a previously unrecognized cause of open-angle glaucoma. Acta Ophthalmol. 2010;88(1):120–124.
18. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117(6):794–801.
19. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38(11):2214–2223.
20. Kakizaki H, Zako M, Nakano T, Asamoto K, Miyaishi O, Iwaki M. The levator aponeurosis consists of two layers that include smooth muscle. Ophthal Plast Reconstr Surg. 2005;21(5):379–382.
21. Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and taflu­prost in human orbital preadiopocytes. J Ocul Pharmacol Ther. 2012;28(2):146–152.
22. Taketani Y, Yamagishi R, Fujishiro T, Igarashi M, Sakata R, Aihara M. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1269–1276.
23. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70(5):563–569.
24. Waheed K, Laganowski H. Bilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis on its withdrawal. Eye (Lond). 2001;15(Pt 3):347–349.
25. Parrish RK, Palmberg P, Sheu WP ; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703.
26. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM ; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110–121.
27. Chiba T, Kashiwagi K, Ishijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004;48(2):141–147.
28. Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68–74.